ViaLase develops the ViaLuxe™ Laser System, which utilizes femtosecond laser technology and high-definition imaging to noninvasively create customized drainage channels in the trabecular meshwork for glaucoma treatment. This approach addresses the limitations of current glaucoma therapies, such as high failure rates and patient noncompliance, by offering a minimally invasive alternative that enhances patient access and recovery.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current glaucoma treatments, such as topical medications and selective laser trabeculoplasty (SLT), often suffer from high failure rates and issues with patient noncompliance. Minimally invasive glaucoma surgeries (MIGS) are invasive and often performed during cataract surgery, limiting patient access. Filtration surgery, a highly invasive procedure, also carries a significant failure rate.
Solution
ViaLase is developing the ViaLuxe™ Laser System, a non-invasive solution for glaucoma treatment that utilizes femtosecond laser technology and high-definition imaging. The system creates customized drainage channels in the trabecular meshwork, aiming to lower intraocular pressure (IOP) without the need for incisions. The non-incisional approach may provide results similar to traditional surgical interventions, while reducing vision-threatening complications and enabling rapid patient recovery. The system's imaging capabilities provide uniform illumination of the angle, enabling undistorted, wide field-of-view visualization.
Target Audience
The primary target audience includes ophthalmologists and glaucoma specialists seeking a non-invasive alternative to traditional glaucoma treatments.
Features
- Femtosecond laser technology for precise creation of drainage channels
- High-definition imaging for unmatched visualization and treatment validation
- Non-invasive, non-incisional approach eliminating the need to open the eye
- Potential for rapid recovery and minimal disruption to patient's quality of life
- Standalone procedure to increase patient access to effective primary open-angle glaucoma (POAG) treatment